Viridian Therapeutics Inc Stock Price, News & Analysis

Viridian Therapeutics (NASDAQ: VRDN) has announced presentations at the 49th Annual Meeting of the North American Neuro-Ophthalmology Society from March 11-16, 2023, in Orlando, Florida. Key highlights include an oral presentation of ongoing Phase 1/2 trial data for VRDN-001, targeting thyroid eye disease (TED), scheduled for March 14. Additionally, four poster presentations will cover the clinical and mechanistic findings of their TED pipeline, which aims to improve treatment for patients. The company is advancing VRDN-001 through its THRIVE Phase 3 trial and planning further studies on other pipeline candidates like VRDN-002 and VRDN-003.

Viridian Therapeutics (Nasdaq: VRDN) announced on March 3, 2023, that its Compensation Committee approved the grant of non-qualified stock options for 337,000 shares to three new employees. These grants were made outside of the Amended and Restated 2016 Equity Incentive Plan and comply with Nasdaq Listing Rule 5635(c)(4). The exercise price is set at the closing stock price on the grant date, with shares vesting over four years. Viridian is focused on developing treatments for serious and rare diseases, particularly advancing its VRDN-001 candidate for thyroid eye disease through both a Phase 3 trial and a Phase 2 proof-of-concept trial.

Viridian Therapeutics (NASDAQ: VRDN) announced a webcast and conference call on March 8, 2023, at 8:00 a.m. ET to discuss its Q4 and full-year 2022 financial results. The session can be accessed via the company’s website under the ‘Events and Presentations’ section. Viridian focuses on developing best-in-class medicines for serious and rare diseases, with ongoing clinical trials for its lead candidate, VRDN-001, targeting thyroid eye disease (TED). The company is conducting a global Phase 3 trial named ‘THRIVE’ and a Phase 2 trial, broadening its pipeline with additional candidates aimed at improving treatment delivery for TED patients.

Viridian Therapeutics, Inc. (NASDAQ: VRDN) announced that its senior management will present at Cowen’s 43rd Annual Health Care Conference on March 8, 2023, at 1:30 p.m. ET in Boston, MA. A live webcast of the presentation will be available in the Investors section of Viridian's website. The company specializes in developing innovative medicines for serious and rare diseases, focusing on thyroid eye disease (TED). Currently, Viridian is advancing VRDN-001 through a global Phase 3 trial named ‘THRIVE’ and a Phase 2 proof-of-concept trial. The company aims to offer convenient treatment options for TED patients.

Viridian Therapeutics, a biopharmaceutical company focused on serious and rare diseases, will participate in a fireside chat at the SVB Securities Virtual Global Biopharma Conference on February 15, 2023, at 1:00 p.m. ET. The event will be accessible via a live webcast on Viridian's website, and a replay will be available afterward. Viridian is advancing its VRDN-001 candidate in global Phase 3 and Phase 2 trials for thyroid eye disease, aiming to deliver best-in-class therapies. The company also develops other candidates targeting autoimmune and rare diseases. For more information, visit viridiantherapeutics.com.

Viridian Therapeutics Appoints New CEO

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company, announced the appointment of Scott Myers as President and CEO, effective February 6, 2023. Myers has over 30 years of experience in the biopharmaceutical sector, succeeding co-founder Jonathan Violin, Ph.D. Under Violin's leadership, the company advanced its first Phase 3 trial in Thyroid Eye Disease (TED). Myers aims to leverage his extensive background to transition Viridian into a fully-integrated biopharmaceutical company, focusing on clinical execution and growth. Additionally, he received an inducement award comprising stock options and restricted stock units.

Viridian Therapeutics, Inc. (Nasdaq: VRDN) announced on February 2, 2023, that its Compensation Committee approved the grant of non-qualified stock options to purchase 332,000 shares to four new employees. This Inducement Grant, made outside the Amended and Restated 2016 Equity Incentive Plan, was essential for the new hires in accordance with Nasdaq Listing Rule 5635(c)(4). The exercise price matches the common stock's closing price on the Grant Date, with shares vesting over four years. The company is focused on creating innovative treatments for serious and rare diseases, particularly advancing candidates for thyroid eye disease.

Viridian Therapeutics (VRDN) announced positive topline data from its Phase 1/2 trial of VRDN-001, an anti-IGF-1R antibody for active thyroid eye disease (TED). In the latest cohort, 3 mg/kg showed significant improvements: 67% of patients were proptosis responders, and 56% overall responders. Across all cohorts, 71% were proptosis responders, with a favorable safety profile noted. The data support a planned once-monthly subcutaneous dosing for VRDN-002 and VRDN-003. The company is progressing towards pivotal trials and expects to advance its subcutaneous program as a convenient treatment option.

Viridian Therapeutics (NASDAQ: VRDN) announced that its CEO, Jonathan Violin, Ph.D., will present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 2:15 p.m. PST in San Francisco. Alongside the presentation, a live Q&A session will begin at 2:35 p.m. PST. Investors can access the live webcast on the company's website, with a replay available until February 8, 2023. Viridian is focused on developing treatments for serious diseases, including ongoing clinical trials for VRDN-001 targeting thyroid eye disease.